In conclusion, this analysis suggests a systemic healing-promoting and skin-stabilizing effect of treatment with allogeneic ABCB5+ MSCs and provides valuable information for the identification of optimal dosing schemes as a further step on the way to efficient treatment strategies to respond to the urgent needs of patients suffering from RDEB. The gene discussed is ABCB5; the disease is recessive dystrophic epidermolysis bullosa.